Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenabasum - Corbus Pharmaceuticals

Drug Profile

Lenabasum - Corbus Pharmaceuticals

Alternative Names: Ajulemic acid; Anabasum; CPL-7075; CT-3; DMH-11C; HU-239; IP-751; JBT-101; Resunab

Latest Information Update: 25 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cervelo Pharmaceuticals; Corbus Pharmaceuticals; Indevus Pharmaceuticals; University of Erlangen-Nuremberg; University of Siena
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Antirheumatics; Cannabinoids; Non-opioid analgesics; Small molecules
  • Mechanism of Action Cannabinoid receptor CB2 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis; Dermatomyositis; Systemic scleroderma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Dermatomyositis; Systemic scleroderma
  • Phase II Cystic fibrosis; Systemic lupus erythematosus
  • Preclinical Rheumatoid arthritis
  • No development reported Pulmonary fibrosis
  • Discontinued Inflammation; Interstitial cystitis; Muscle spasticity; Neuropathic pain; Pain; Poisoning

Most Recent Events

  • 09 Aug 2021 Biomarkers information updated
  • 28 Jul 2021 Corbus Pharmaceuticals and the National Institute of Allergy and Infectious Diseases complete a phase II trial in Systemic lupus erythematosus in USA (PO) (NCT03093402)
  • 24 Jun 2021 Topline efficacy and safety data from a phase III DETERMINE trial in Dermatomyositis released by Corbus Pharmaceuticals
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top